banner medline tsn
МЕДЛАЙН.РУ
Содержание журнала

Архив

Редакция
Учредители

Федеральное государственное бюджетное учреждение науки
Институт теоретической и экспериментальной биофизики
Российской академии наук


ООО "ИЦ КОМКОН"

ФГБУ НКЦТ им. С.Н. Голикова ФМБА России

Адрес редакции и реквизиты

192012, Санкт-Петербург, ул.Бабушкина, д.82 к.2, литера А, кв.378

Свидетельство о регистрации электронного периодического издания ЭЛ № ФС 77-37726 от 13.10.2009
Выдано - Роскомнадзор

ISSN 1999-6314


Клиническая медицина » Терапия • Кардиология

Том: 27
Статья: « 36 »
Страницы:. 880-909
Опубликована в журнале: 4 сентября 2026 г.
English version

Cтатины: особенности действия и приверженность терапии

Плужников Н.В., Чепур С.В.

Федеральное государственное бюджетное учреждение «Государственный научно-исследовательский испытательный институт военной медицины» Минобороны России, 195043, Россия, Санкт-Петербург, ул. Лесопарковая, д. 4.


Резюме
Статины составляют весьма обширную, глубоко изученную и широко назначаемую группу лекарственных средств для снижения уровня холестерина в плазме крови. Помимо гиполипидемического действия постоянно выявляют все новые и новые биологические эффекты статинов. Они обладают выраженным противовоспалительным действием и антиоксидантной активностью; проявляют антибактериальные свойства и ингибируют метаногенную активность архей; способны предотвращать и купировать стресс эндоплазматического ретикулума, ингибировать эпителиально-мезенхимальный переход, что определяет их положительное влияние на показатели выживаемости при злокачественных новообразованиях; предотвращать и купировать эндотелиальную дисфункцию. Статины оказывают анаболическое действие на костную систему, минимизируют вероятность прогрессирующего фиброза и декомпенсированного цирроза печени, способствуют сохранению функции почек. Побочное действие статинов сопряжено как с их основной фармакологической активностью, связанной с конкурентным ингибированием 3-гидрокси-3-метилглутарил-кофермент А редуктазы (ингибированию продукции соединений, синтез которых проходит по мевалонатному пути, падению доступности холестерина для регенерации структур мозга и синтеза половых гормонов и др.), так и проявлениями гепатотоксичного и диабетогенного действия. Статины — относительно безопасные препараты, а доказанная польза терапии ими гиперлипидемических состояний значительно превышает риск возникновения побочных эффектов.


Ключевые слова
статины, механизм действия, побочные эффекты, ГМГ-СоА-редуктаза.


(статья в формате PDF. Для просмотра необходим Adobe Acrobat Reader)



открыть статью в новом окне

Список литературы

Martin S.S., Aday A.W., Allen N.B. et al. 2025 Heart Disease and Stroke Statistics: a report of US and Global Data from the American Heart Association. Circulation. 2025; 151 (8): e41-e660. https://doi.org/10.1161/CIR.0000000000001345.


2. Friedman M., Friedland G.W. Medicine`s ten greatest discoveries. New Haven, CT: Yale University Press; 1998. https://doi.org/10.1136/bmj.319.7206.389.


3. Kennedy E.P., Westheimer F.H. Nobel laureates: Bloch and Lynen win prize in medicine and physiology. Science. 1964; 146 (3643): 504-506. https://doi.org/10.1126/science.146.3643.504.


4. Endo A. A historical perspective on the discovery of statins. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2010; 86 (5): 484-493. https://doi.org/10.2183/pjab.86.484.


5. Alberts A.W. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 1988; 62 (15): 10J-15J. https://doi.org/10.1016/0002-9149(88)90002-1.


6. Rosenberg J., Lampridou S., Moores A. et al. A Systematic Review Uncovering Modifiable Influences on Statin Adherence. Patient Prefer Adherence. 2025;. 19: 29-48. https://doi.org/10.2147/PPA.S502645.


7. Khatiwada N., Hong Z. Potential benefits and risks associated with the use of statins. Pharmaceutics. 2024; 16 (2): 214. https://doi.org/10.3390/pharmaceutics16020214.


8. He W.B., Ko H.T.K., Curtis A.J. et al. The effects of statins on cardiovascular and inflammatory biomarkers in primary prevention: a systematic review and meta-analysis. Heart Lung Circ. 2023; 32 (8): 938-948. https://doi.org/10.1016/j.hlc.2023.04.300.


9. Kandelouei T., Abbasifard M., Imani D. et al. Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm. 2022; 2022 (1): 8732360. https://doi.org/10.1155/2022/8732360.


10. Khan S., Huda B., Bhurka F. et al. Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci. 2025; 26 (17): 8429. https://doi.org/10.3390/ijms26178429.


11. Masadeh M., Mhaidat N., Alzoubi K. et al. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann. Clin. Microbiol. Antimicrob. 2012; 11: 13. https://doi.org/10.1186/1476-0711-11-13.


12. Vogeli B., Shima S., Erb T.J., Wagner T. Crystal structure of archeal HMG-CoA reductase: insights into structural changes of the C-terminal helix of the class-I enzyme. FEBS Lett. 2019; 593 (5): 543-553. https://doi.org/10.1002/1873-3468.13331.


13. Morales W., Marsh E.S., Yu A. et al. Mo2051 lovastatin improves stool form in Methanobrevibacter Smithii colonized rats with constipation. Gastroenterology. 2015; 148 (4): S779-S780. https://doi.org/10.1016/S0016-5085(15)32660-3.


14. Sisek A.A., Szymanska E., Aleksandrzak-Piekarczyk T., Cukrowska B. The role of methanogenic archaea in inflammatory bowel disease - a review. J. Pers. Med. 2024; 14 (2): 196. https://doi.org/10.3390/jpm14020196.


15. Campbell A., Gdanetz K., Schmidt A.W., Schmidt T.M. H2 generated by fermentation in the human gut microbiome influences metabolism and competitive fitness of gut butyrate producers. Microbiome. 2023; 11 (1): 133. https://doi.org/10.1186/s40168-023-01565-3.


16. Tian Y., Zhang Y., Wang Y. et al. Hydrogen, a novel therapeutic molecule, regulates oxidative stress, inflammation, and apoptosis. Front. Physiol. 2021; 12: 789507. https://doi.org/10.3389/fphys.2021.789507.


17. Mollazadeh H., Atkin S.L., Butler A.E. et al. The effect of statin therapy on endoplasmic reticulum stress. Pharmacol. Res. 2018; 137: 150-158. https://doi.org/10.1016/j.phrs.2018.10.006.


18. Fan Z., Jiang H., Wang Z., Qu J. Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1. Oncol. Rep. 2016; 36 (2): 1016-1022. https://doi.org/10.3892/or.2016.4897.


19. Scott O.W., Tin Tin S., Cavadino A., Elwood J.M. Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumor characteristics. Br. J. Cancer. 2025; 133 (4): 539-554. https://doi.org/10.1038/s41416-025-03070-w.


20. Jia X., Lu Y., Xu Z., Mu Q. Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis. Front. Oncol. 2023; 13: 1256747. https://doi.org/10.3389/fonc.2023.1256747.


21. Tong H., Zhang X., Meng X. et al. Simvastatin inhibits activation of NADPH Oxidase/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models. Front. Mol. Neurosci. 2018; 11: 165. https://doi.org/10.3389/fnmol.2018.00165.


22. Parihar A., Parihar M.S., Zenebe W.J., Ghafourifar P. Statins lower calcium-induced oxidative stress in isolated mitochondria. Hum. Exp. Toxicol. 2012; 31 (4): 355-363. https://doi.org/10.1177/0960327111429141.


23. Buyukhatipoglu H., Sezen Y., Yildiz A. et al. Effects of statin use on total oxidant and antioxidant capacity and ceruloplasmin activity. Clin. Invest. Med. 2010; 33 (5): E313-E320. https://doi.org/10.25011/cim.v33i5.14357.


24. Ferretti G., Bacchetti T. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res. 2015; 60 (Pt 2): 50-73. https://doi.org/10.1016/j.plipres.2015.08.003.


25. Zinellu A., Mangoni A. A systematic review and meta-analysis of the effect of statins on glutathione peroxidase, and superoxide dismutase, and catalase. Antioxidants. 2021; 10 (11): 1841. https://doi.org/10.3390/antiox10111841.


26. Piechota-Polanczyk A., Jozkowicz A. The role of statins in the activation of heme oxygenase-1 in cardiovascular diseases. Curr. Drug Targets. 2017; 18 (6): 674-688. https://doi.org/10.2174/1389450117666160401123600.


27. Mansouri A., Reiner Ž., Ruscica M. et al. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J. Clin. Med. 2022; 11 (5): 1313. https://doi.org/10.3390/jcm11051313.


28. Tastan B., Arioz B.I., Genc S. Targeting NLRP3 inflammasome with Nrf2 inducers in central nervous system disorders. Front. Immunol. 2022; 13: 865772. https://doi.org/10.3389/fimmu.2022.865772.


29. Augustin H.G., Kozian D.H., Johnson R.C. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioassays. 1994; 16 (12): 901-906. https://doi.org/10.1002/bies.950161208.


30. Yau J.W., Teon H., Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 2015; 15: 130. https://doi.org/10.1186/s12872-015-0124-z.


31. Sandoo A., van Zanten J.J., Metsios G.S. et al. The endothelium and its role in regulating vascular tone. Open Cardiovasc. Med. J. 2010; 4: 302-312. https://doi.org/10.2174/1874192401004010302.


32. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999; 56 (3): 794-814. https://doi.org/10.1046/j.1523-1755.1999.00610.x.


33. Widmer R.J., Lerman A. Endothelial dysfunction and cardiovascular disease. Glob. Cardiol. Sci. Pract. 2014; 2014 (3): 291-308. https://doi.org/10.5339/gcsp.2014.43.


34. Jantzen F., Konemann S., Wolff B. et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J. Physiol. Pharmacol. 2007; 58 (3): 503-514. PMID: 17928646.


35. Liu C., Shen M., Tan W.L.W. et al. Statins improve endothelial function via suppression of epigenetic-driven EndMT. Nat. Cardiovasc. Res. 2023; 2 (5): 467-485. https://doi.org/10.1038/s44161-023-00267-1.


36. Sahebkar A., Kotani K., Serban C. et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015; 241 (2): 433-442. https://doi.org/10.1016/j.atherosclerosis.2015.05.022.


37. Jamialahmadi T., Reiner Ž., Simental-Mendia L.E. et al. Effect of statins on arterial wall inflammation as assessed by 18F-FDG PET CT: an updated systematic review and meta-analysis. J. Inflamm. 2024; 21 (1): 52. https://doi.org/10.1186/s12950-024-00421-x.


38. Hölschermann H., Schuster D., Parviz B. et al. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis. 2006; 185 (2): 240-245. https://doi.org/10.1016/j.atherosclerosis.2005.06.019.


39. Sen-Banerjee S., Mir S., Lin Z. et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005; 112 (5): 720-726. https://doi.org/10.1161/CIRCULATIONAHA.104.525774.


40. Nenna A., Nappi F., Lusini M. et al. Effect of statins on platelet activation and function: from molecular pathways to clinical effects. Biomed. Res. Int. 2021; 2021: 6661847. https://doi.org/10.1155/2021/6661847.


41. Ayodele O., Cabral H.J., McManus D.D., Jick S.S. Risk of venous thromboembolism in statin users compared to fibrate users in the United Kingdom clinical practice research datalink (UK CPRD). Gold. Clin. Epidemiol. 2024; 16: 683-697. https://doi.org/10.2147/CLEP.S481448.


42. Issa D.R., Nassar M., Elamrousy W. Immediately placed implants using simvastatin and autogenous tooth graft combination in periodontally compromised sites: a randomized controlled trial. Clin. Oral. Investig. 2024; 28 (4): 210. https://doi.org/10.1007/s00784-024-05596-4.


43. Imprialos K.P., Stavropoulos K., Doumas M. et al. The potential role of statins in treating liver disease. Expert. Rev. Gastroenterol. Hepatol. 2018; 12 (4): 331-339. https://doi.org/10.1080/17474124.2018.1439379.


44. Anjum I., Akmal M., Hasnain N. et al. Statins role in preventing contrast-induced acute kidney injury: a scoping review. Hong Kong Med. J. 2019; 25 (3): 216-221. https://doi.org/10.12809/hkmj187459.


45. Pinal-Fernandez I., Casal-Dominiguez M., Mammen A.L. Statins: pros and cons. Med. Clin. 2018; 150 (10): 398-402. https://doi.org/10.1016/j.medcli.2017.11.030.


46. Mantle D., Hargreaves I.P., Domingo J.C., Castro-Marrero J. Mitochondrial dysfunction and coenzyme Q10 supplementation in post-viral fatigue syndrome: an overview. Int. J. Mol. Sci. 2024; 25 (1): 574. https://doi.org/10.3390/ijms25010574.


47. Bagley W.H., Yang H., Shah K.H. Rhabdomyolysis. Intern. Emerg. Med. 2007; 2 (3): 210-218. https://doi.org/10.3390/ijms25010574.


48. Azemawach V., Movahed M.R., Centuori P. et al. State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovasc. Drugs Ther. 2019; 33 (5): 625-639. https://doi.org/10.1007/s10557-019-06904-x.


49. Vinci P., Panizon E., Tosoni L.M. et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int. J. Mol. Sci. 2021; 22 (21): 11687. https://doi.org/10.3390/ijms222111687.


50. Ramkumar S., Raghunath A., Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol. Sin. 2016; 32 (6): 631-639. https://doi.org/10.6515/acs20160611a.


51. Matzno S., Yasuda S., Juman S. et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J. Pharm. Pharmacol. 2005; 57 (11): 1475-1484. https://doi.org/10.1211/jpp.57.11.0014.


52. Lindsay C., Musgaard M., Russel A.J., Sitsapesan R. Statin activation of skeletal ryanodine receptors (RyR1) is a class effect but separable from HMG-CoA reductase. Br. J. Pharmacol. 2022; 179 (21): 4941-4957. https://doi.org/10.1111/bph.15893.


53. Yu D., Liao J.K. Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc. Res. 2022; 118 (2): 413-423. https://doi.org/10.1093/cvr/cvab032.


54. Cohen A.W., Combs T.P., Scherer P.E., Lisanti M.P. Role of caveolin and caveolae in insulin signaling and diabetes. Am. J. Physiol. Endocrinol. Metab. 2003; 286 (6): E1151-E1160. https://doi.org/10.1152/ajpendo.00324.2003.


55. Grunwald S.A., Haafke S., Grieben U. et al. Statins Aggravate the Risk of Insulin Resistance in Human Muscle. Int. J. Mol. Sci. 2022; 23 (4): 2398. https://doi.org/10.3390/ijms23042398.


56. Takei S., Nagashima S., Takei A. et al. β-Cell-specific deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase causes overt diabetes due to reduction of β cell mass and impaired insulin secretion. Diabetes. 2020; 69 (11): 2352-2363. https://doi.org/10.2337/db19-0996.


57. Fu Z.D., Cui J.Y., Klaassen C.D. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. J. Lipid. Res. 2014; 55 (12): 2576-2586. https://doi.org/10.1194/jlr.M053124.


58. Kim J., Lee H., An J. et al. Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia. Front. Microbiol. 2019; 10: 1947. https://doi.org/10.3389/fmicb.2019.01947.


59. Sun C., Wang Z., Hu L. et al. Targets of statins intervention in LDL-C metabolism: gut microbiota. Front. Cardiovasc. Med. 2022; 9: 972603. https://doi.org/10.3389/fcvm.2022.972603.


60. Zacharia G., Jacob A., Karichery M., Sasibharan A. Impact of statin in the liver: a bane or a boon? Canad. Liver J. 2024; 7 (1): 490-499. https://doi.org/10.3138/canlivj-2023-0028.


61. Wang B., Huang S., Li S. et al. Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Events Reporting System database. Front. Pharmacol. 2025; 15: 1502791. https://doi.org/10.3389/fphar.2024.1502791.


62. Bitzur R. Remembering statins: do statins have adverse cognitive effects? Diabetes Care. 2016; 39(Suppl 2): S253-S259. https://doi.org/10.2337/dcS15-3022.


63. Dietschy J.M., Turley S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid. Res. 2004; 45 (8): 1375-1397. https://doi.org/10.1194/jlr.R400004-JLR200.


64. Benarroch E.E. Brain cholesterol metabolism and neurologic disease. Neurology. 2008; 71 (17): 1368-1373. https://doi.org/10.1212/01.wnl.0000333215.93440.36.


65. Ott B.R., Daiello L.A., Dahabreh I.J. et al. Do statin impair cognition? A systematic review and meta-analysis of randomized controlled trials. J. Gen. Intern. Med. 2015; 30 (3): 348-358. https://doi.org/10.1007/s11606-014-3115-3.


66. Olmastroni E., Molari G., De Beni N. et al. Statin use and risk of dementia or Alzheimer`s disease: a systematic review and meta-analysis of observational studies. Eur. J. Prev. Cardiol. 2022; 29 (5): 804-814. https://doi.org/10.1093/eurjpc/zwab208.


67. Xiao M., Li L., Zhu W. et al. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system. Expert Rev. Clin. Pharmacol. 2024; 17 (3): 255-261. https://doi.org/10.1080/17512433.2024.2311875.


68. Haney S.L., Holstein S.A. Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma. Int. J. Mol. Sci. 2022; 24 (1): 111. https://doi.org/10.3390/ijms24010111.


69. Shamma A., Takegami Y., Miki T. et al. Rb regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell. 2009; 15 (4): 255-269. https://doi.org/10.1016/j.ccr.2009.03.001.


70. Liu C., Zuo W., Yan G. et al. Granulosa cell mevalonate pathway abnormalities contribute to oocyte meiotic defects and aneuploidy. Nat. Aging. 2023; 3 (6): 670-687. https://doi.org/10.1038/s43587-023-00419-9.


71. Wang Y., Tinsley B., Spolitu S. et al. Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9. J. Lipid Res. 2024; 65 (3): 100515. https://doi.org/10.1016/j.jlr.2024.100515.


72. Suen T.K., Al B., Ulas T. et al. Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition. Immunology. 2025; 175 (3): 300-322. https://doi.org/10.1111/imm.13931.


73. Hussain A., Keler J., Ray S.D. The benefits outweigh the risks of treating hypercholesterolemia: the statin dilemma. Cureus. 2023; 15 (1): e33648. https://doi.org/10.7759/cureus.33648.


74. Calabrese E., Pressman P. Enhancing the human health and lifespan: a targeted strategy emphasizing statins. Biogerontology. 2024; 25 (5): 883-890. https://doi.org/10.1007/s10522-024-10112-y.